Table 1 Patient characteristics in test group
From: AI-based quantification of whole-body tumour burden on somatostatin receptor PET/CT
Characteristic | Value (n = 30) |
|---|---|
Sex | |
Female | 16 |
Mean age at PET/CT (y) | 66.4 (SD 12.8) |
PET with | |
DOTA-TATE | 9 |
DOTA-TOC | 21 |
Low-dose CT | 7 |
Diagnostic CT with iv. contrast | 21 |
Diagnostic CT without iv. contrast | 2 |
Reason for PET/CT | |
First examination | 7 |
Follow-up after treatment | 13 |
Follow-up after surgery | 1 |
Suspected progressive disease | 5 |
Evaluation before decision about PRRT | 4 |
Primary tumour | |
No verified NET and no SSTR-expressing lesion | 3 |
Small bowel | 18 |
Pancreas | 3 |
Medullary thyroid cancer | 2 |
Stomach | 1 |
MEN 1 | 1 |
Atypical carcinoid | 1 |
Small cell neuroendocrine carcinoma | 1 |
Ki-67 (%) | |
< 3 | 17 |
3 to ≤ 20 | 7 |
> 20 | 2 |
Unknown | 1 |
Earlier treatment before PET/CT | |
Surgery | 22 |
PRRT | 2 |
Chemotherapy | 2 |
Somatostatin analog | 1 |
Ongoing treatment with somatostatin analog | 13 |
TNM stage at PET/CT | |
Only primary tumour | 5 |
Loco-regional disease | 2 |
Metastatic | 18 |
NET verified pathological diagnose but no remaining tumour on PET/CT | 2 |
No NET | 3 |
Distribution of somatostatin receptor-expressing lesions* | |
Pathological uptake | 25 |
Liver | 7 |
Lung | 3 |
Bone | 9 |
Abdomen (except liver) | 9 |
Lymph nodes | 10 |
Other locations | 4 |
No pathological uptake | 5 |